Talphera Earnings Call Highlights NEPHRO Trial Momentum

Talphera, Inc. ((TLPH)) has held its Q1 earnings call. Read on for the main highlights of the call.

Talphera’s latest earnings call struck a cautiously optimistic tone as management highlighted strong momentum in its NEPHRO CRRT program while acknowledging clear funding and execution risks. Enrollment is now well past the halfway mark, clinicians report favorable real‑world experience with Niyad dosing, and leadership is targeting a 2027 PMA filing, but higher costs and reliance on conditional financing temper the otherwise constructive outlook.

Enrollment Progress & Milestones

Talphera reported that the NEPHRO CRRT trial crossed the 50% enrollment threshold in early March 2026 and has since “well exceeded” that mark. The company expects to complete enrollment this year, positioning Niyad for a planned PMA submission in 2027, with 9 of 12 activated sites aligned to the new target profile and accounting for more than 90% of patients.

Site Quality, KOL and Investigator Support

Management emphasized that nephrologist‑led centers and principal investigators are driving the trial with high engagement and operational support. Key opinion leaders highlighted nafamostat’s decades of use outside the U.S., reinforcing the perception that Niyad is addressing a clear unmet need and helping sustain enthusiasm among clinical staff.

Operational & Clinical Performance (Dosing Stability)

The NEPHRO study’s design allows for quick data generation, with a 24‑hour primary endpoint and a 72‑hour secondary endpoint that compresss the time to top‑line results. Bedside ACT monitoring shows about 70% of patients reach target anticoagulation at the starting dose and nearly all are within range by the end of the first hour, underscoring dosing stability and ease of use.

Cash Position and Financing Activity

As of March 31, 2026, Talphera held $21.1 million in cash and had drawn a $4.1 million tranche earlier in the quarter. Management said two remaining conditional tranches totaling roughly $16 million are expected around study completion and top‑line data, and together with existing cash should be sufficient to fund operations through a potential Niyad PMA approval.

Fast Data Readout Expectation

Because NEPHRO’s endpoints are assessed within 24 and 72 hours, the company believes it can move rapidly from last‑patient‑out to headline results. Talphera plans to announce LPO and deliver top‑line data within about a month thereafter, reiterating guidance for a second‑half‑2026 readout that could be a major catalyst for investors.

Increase in Operating Expenses

Operating leverage remains a pressure point, with Q1 2026 cash operating expenses rising to $3.9 million from $2.9 million a year earlier. Even excluding stock‑based compensation, expenses climbed to $3.7 million from $2.7 million, a jump management attributes to higher Niyad development costs as enrollment ramps and to increased general and administrative spending.

Reliance on Conditional Financing Tranches

The company’s funding runway is notably tied to two milestone‑based tranches that together total about $16 million and are expected around the time of top‑line data. While management believes these funds will arrive as planned, the conditional terms introduce execution risk, as any delay or unmet milestone could pressure liquidity and the timing of key regulatory steps.

Concentration of Enrollment & Late Site Additions

Talphera disclosed that 9 of 12 activated sites have enrolled more than 90% of patients, highlighting a concentration in high‑performing centers that could amplify variability if any site underdelivers. Two additional sites will be added late and are not expected to materially contribute, meaning the existing core centers will remain central to hitting enrollment targets.

Timeline and Enrollment Variability Risk

Management reiterated second‑half‑2026 guidance for top‑line NEPHRO data but cautioned that enrollment naturally “ebbs and flows” based on patient flow and qualifying criteria. Any sustained slowdown could push out last‑patient‑out, potentially delaying both the data readout and the subsequent PMA timeline investors are closely tracking.

Forward‑Looking Guidance and Outlook

Looking ahead, Talphera expects to finish NEPHRO enrollment in 2026, announce last‑patient‑out, and provide top‑line data roughly one month later, consistent with a second‑half‑2026 target. Management believes its current cash plus anticipated conditional financings should fund operations through a planned 2027 PMA filing for Niyad, though they do not intend to provide interim enrollment updates before LPO.

Talphera’s earnings call painted a picture of a company executing well on its pivotal trial while navigating the familiar risks of a late‑stage biotech. Strong clinical engagement, promising dosing performance, and a clear regulatory roadmap underpin the bullish case, but higher burn and reliance on conditional capital mean investors will need to watch both the enrollment curve and financing milestones closely.